Circulating Tumour DNA as a Sensitive and Specific Marker of Response to Therapy and of Occult Disease in Colorectal Cancer

Not Applicable

Recruiting

• Conditions: Patients with resectable colorectal cancer liver metastases; Cancer - Bowel - Back passage (rectum) or large bowel (colon)

• Registration Number: ACTRN12612000345886
• Lead Sponsor: udwig Institute for Cancer Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-03-26
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Patients with histologically confirmed primary colorectal cancer
2. Patients with resected primary tumours or planned for curative primary tumour resection.
3. Patients with resectable liver metastases following workup including CT scans of chest, abdomen and pelvis (or MRI if unable to undertake CT scan) and whole body PET scan.
4. Patients fit for surgery
5. Patients fit for combination chemotherapy (5-FU and oxaliplatin)
6. Patients willing to provide written informed consent

Exclusion Criteria

1. History of another primary cancer within the last 5 years, with the exception of non-melanomatous skin cancer and carcinoma in situ of the cervix.
2. Medical or psychiatric condition or occupational responsibilities that may preclude compliance with the protocol
3. Patients that are not accessible for follow-up

Study & Design

• Study Type: Observational
• Study Design: Not specified